Get started
Work

Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors

Year: 2020
Type: article
DOI: 10.1038/s43018-020-0047-1
Authors: Pedram Razavi, Maura N. Dickler, Payal D. Shah, Weiyi Toy, David N. Brown, Helen H. Won, Bob T. Li, Ronglai Shen, Neil Vasan, Shanu Modi, Komal Jhaveri, Betty Ann Caravella, Sujata Patil, Pier Selenica, Stephen Zamora, Aimee M. Cowan, Elizabeth Comen, Andy Singh, Anne Covey, Michael F. Berger, Clifford A. Hudis, Larry Norton, Rebecca J. Nagy, Justin I. Odegaard, Richard B. Lanman, David B. Solit, Mark E. Robson, Mario E. Lacouture, Edi Brogi, Jorge S. Reis-Filho, Mary Ellen Moynahan, Maurizio Scaltriti, Sarat Chandarlapaty
Institutions: Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, Eli Lilly (United States), University of Pennsylvania, Guardant (United States), American Society of Clinical Oncology
Language: English
Field: Medicine
Open Access status: closed
Awards: G1007166040, G128855785, Defining mechanisms of resistance to hormonal therapy in breast cancer, G1888143242, G2963763408, G3294690985, Unraveling resistance to PI3K-alpha inhibitors in breast cancer, Therapeutic approaches to ER mutant breast cancer, Cancer Center Support Grant
OpenAlex ID: W3012647537
FWCI: 12.3
Cites: 63
Cited by: 160
Related to: 10